Pharmacokinetics and pharmacodynamics of some oximes and associated therapeutic consequences: A critical review

Journal of Applied Toxicology

Volumn 30, Issue 8, 2010, Pages 719-729

  Voicu, Victor A ^a   Bajgar, Jiri ^b   Medvedovici, Andrei ^c   Radulescu, Flavian Stefan ^a   Miron, Dalia Simona ^a  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b UNIVERSITY OF DEFENCE   (Czech Republic)

^c UNIVERSITY OF BUCHAREST   (Romania)

Author keywords

Acetylcholinesterase; Blood brain barrier; Organophosphorus compounds; Oximes

Indexed keywords

ACETYLCHOLINESTERASE; OBIDOXIME; ORGANOPHOSPHORUS COMPOUND; OXIME; PRALIDOXIME; TRIMEDOXIME;

BLOOD BRAIN BARRIER; BRAIN DAMAGE; BRAIN REGION; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG PENETRATION; ENZYME REACTIVATION; HYDROPHOBICITY; INDUCED HYPOTHERMIA; INTOXICATION; LIPOPHILICITY; MOUSE; NEUROPROTECTION; NONHUMAN; PHARMACODYNAMICS; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; REVIEW; SEIZURE;

ACETYLCHOLINESTERASE; ANTIDOTES; BLOOD-BRAIN BARRIER; BRAIN; CHOLINESTERASE REACTIVATORS; HYPOTHERMIA; ORGANOPHOSPHORUS COMPOUNDS; OXIMES; SEIZURES; TISSUE DISTRIBUTION;

EID: 78649662161     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1561     Document Type: Review

References (97)

1. Abraham MH. 2004. The factors that influence permeation across the blood-brain barrier. Eur. J. Med. Chem. 39: 235-40; doi: 10.1016/j.ejmech.2003.12.004.
2. Adams GK 3rd, Yamamura HI, O'Leary JF. 1976. Recovery of central respiratory function following anticholinesterase intoxication. Eur. J. Pharmacol. 38(1): 101-112; doi: 10.1016/0014-2999(76)90206-5.
3. Antonijevic B, Stojiljkovic MP. 2007. Unequal efficacy of pyridinium oximes in acute organophosphate poisoning. Clin. Med. Res. 5: 71-82; doi: 10.3121/cmr.2007.701.
4. Askew BM. 1957. Oximes and atropine in sarine poisoning. Brit. J. Pharmacol. 12: 340-343.
5. Bajgar J. 1971. Inhibition of acetylcholinesterase in different parts of the brain of mice by isopropyl methylphosphonofluridate in vitro and in vivo. Arch. Toxicol. 27: 233-241; doi: 10.1007/BF00315046.
6. Bajgar J. 1972a. Inhibition of acetylcholinesterase in different parts of the brain of mice by isopropyl methylphosphonofluridate: in vitro and in vivo experiments. Biochem. Pharmacol. 21: 687-694; doi: 10.1016/0006-2952(72)90061-5.
7. Bajgar J. 1972b. Time course of acetylcholinesterase inhibition in medulla oblongata of the rat by O-ethyl S-(2-dimethyl-aminoethyl) methylphosphonothioate in vivo. Br. J. Pharmacol. 45: 368-371.
8. Bajgar J. 1991. The influence of inhibitors and other factors on cholinesterases. Sbor ved. Prac. LF UK (Hradec Kralove) 34: 5-77.
9. Bajgar J. 2004. Organophosphates/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment. Adv. Clin. Chem. 38: 151-216; doi: 10.1016/S0065-2423(04)38006-6.
10. Bajgar J, Patocka J, Jakl A, Hrdina V. 1975. Antidotal therapy and changes of acetylcholinesterase activity following isopropyl methylphosphonofluoridate intoxication in mice. Acta Biol. Med. Germ. 34: 1049-1055.
11. Bajgar J, Michalek H, Bisso GM. 1995. Differential reactivation by HI-6 in vivo of paraoxon-inhibited rat brain acetylcholinesterase molecular forms. Neurochem. Int. 26: 347-350; doi: 10.1016/0197-0186(94)00151-J.
12. Bajgar J, Hajek P, Karasova J, Slizova D, Krs O, Kuca K, Jun D, Fusek J, Capek L. 2007a. Inhibition of acetylcholinesterase in different structures of the rat brain fallowing soman intoxication pretreated with huperzine A. Int. J. Mol. Sci. 8: 1165-1176; doi: 10.3390/i8111165.
13. Bajgar J, Hajek P, Slizova D, Krs O, Fusek J, Kuca K, Jun D, Bartosova L, Blaha V. 2007b. Changes of acetylcholinesterase activity in different rat brain areas following intoxication with nerve agents: biochemical and histochemical study. Chem. Biol. Interact. 165: 14-21; doi: 10.1016/j.cbi.2006.10.006.
14. Bajgar J, Fusek J, Kassa J, Jun D, Kuca K, Hajek P. 2008. An attempt to assess functionally minimal acetylcholinesterase aktivity necessary for survival of rats intoxicated with nerve agents. Chem. Biol. Interact. 175: 281-285; doi: 10.1016/j.cbi.2008.05.015.
15. Ballabh P, Braun A, Nedergaard M. 2004. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis. 16: 1-13; doi: 10.1016/j.nbd.2003.12.016.
16. Bodor N, Shek E, Higuchi T. 1975. Delivery of a quaternary pyridinium salt across the blood-brain barrier by its dihydropyridine derivative. Science 190: 155-156; doi: 10.1126/science.1166305.
17. Bodor N, Shek E, Higuchi T. 1976. Improved delivery through biological membranes. 1. Synthesis and properties of 1-methyl-1, 6-dihydropyridine-2-carbaldoxime, a pro-drug of N-methylpyridinium-2-carbaldoxime chloride. J. Med. Chem. 19: 102-107; doi: 10.1021/jm00223a017.
18. Bodor N, Roller RG, Selk SJ. 1978. Elimination of a quaternary pyridinium salt delivered as its dihydropyridine derivative from brain of mice. J. Pharm. Sci. 67: 685-687; doi: 10.1002/jps.2600670531.
19. Bosković B, Tadić V, Kusić R. 1980. Reactivating and protective effects of Pro-2PAM in mice poisoned with paraoxon. Toxicol. Appl. Pharmacol. 55: 32-36; doi: 10.1016/0041-008X(80)90216-1.
20. Capacio BR, Whalley CE, Byers CE, McDonough JH. 2001. Intramuscular diazepam pharmacokinetics in soman-exposed guinea pigs. J. Appl. Toxicol. 21: S67-S74; doi: 10.1002/jat.813.
21. Carpentier P, Foquin-Tarricone A, Bodjarian N, Rondouin G, Lerner-Natoli M, Kamenka JM, Blanchet G, Lallement G. 1994. Anticonvulsant and antilethal effects of the phencyclidine derivative TCP in soman poisoning. Neurotoxicology 15: 837-851.
22. Cassel G, Karlsson L, Waara L, Ang KW, Göransson-Nyberg A. 1997. Pharmacokinetics and effects of HI 6 in blood and brain of soman-intoxicated rats: a microdialysis study. Eur. J. Pharmacol. 332: 43-52; doi: 10.1016/S0014-2999(97)01058-3.
23. Castro AT, Figueroa-Villar JD, 2002. Molecular structure, conformational analysis and charge distribution of pralidoxime: ab initio and DFT studies, Int. J. Quantum Chem. 89: 135-146; doi: 10.1002/qua.10302.
24. Clement JG. 1979. Efficacy of pro-PAM (N-methyl-1, 6-dihydropyridine-2-carbaldoxime hydrochloride) as a prophylaxis against organophosphate poisoning. Toxicol. Appl. Pharmacol. 47: 305-311; doi: 10.1016/0041-008X(79)90325-9.
25. Clement JG. 1992. Central activity of acetylcholinesterase oxime reactivators. Toxicol. Appl. Pharmacol. 112: 104-109; doi: 10.1016/0041-008X(92)90285-Z.
26. Committee on Toxicology. 1982. Possible Long-term Effects of Short-term Exposure to Chemical Agents. Volume 1: Anticholinesterase and Anticholinergics. Board on Toxicology and Environmental Health Hazards, Comission on Life Sciences, National Research Council, Panel on Anticholinesterase Chemicals, Panel of Anticholinergic Chemicals. National Academy Press: Washington, DC.
27. Committee on Toxicology. 1984. Possible Long-term Effects of Short-Term Exposure to Chemical Agents. Volume 2: Cholinersterase reactivators, Psychochemicals and Iritants and Vesicants. Board on Toxicology and Environmental Health Hazards Assembly of Life Sciences, Panel on Cholinesterase Reactivator Chemicals, Panel of Psychochemicals, Panel of Iritants and Vesicants. National Academy Press: Washington, DC.
28. Csermely T, Kalász H, Petroianu GA, Kuca K, Darvas F, Ludányi K, Mudhafar A, Tekes K. 2008. Analysis of pyridinium aldoximes - a chromatographic approach. Curr. Med. Chem. 15: 2401-2418; doi: 10.2174/092986708785909175.
29. Davies DR, Green AL. 1959. The chemotherapy of poisoning by organophosphate anticholinesterases. Br. J. Indust. Med. 16: 128-134.
30. Dawson RM. 1994. Review of oximes available for treatment of nerve agent poisoning. J. Appl. Toxicol. 14(5): 317-331; doi: 10.1002/jat.2550140502.
31. Dishovski CH. 2005. Medical Aspects of Chemical and Biological Terorism. Publication House of Union of Scientists in Bulgaria: Sofia.
32. Fagerholm U. 2007. The highly permeable blood-brain barrier: an evaluation of current opinions about brain uptake capacity. Drug Discov. Today 12: 1076-1082; doi: 10.1016/j.drudis.2007.10.005.
33. Falb A, Erdmann WD. 1969. Penetration of 14C-obidoxime through the so-called blood-brain barrier of mice and rats. Arch. Toxicol. 24: 123-132; doi: 10.1007/BF00577820.
34. Firemark H, Barlow CF, Roth LJ. 1964. The penetration of 2-PAM-C14 into brain and the effect of cholinesterase inhibitors on its transport. J. Pharmacol. Exp. Ther. 145: 252-265.
35. Goodman LS and Gilman A. 2006. The Pharmacological Basis of Therapeutics, 11th edn. McGraw Hill: New York
36. Gordon CJ, Mack CM, Rowsey PJ. 2005. Temperature regulation in experimental mammals and humans exposed to organophosphate and carbamate agents. In Toxicology of Organophosphate and Carbamate Compounds, Gupta R (ed.). Academic Press: New York; 549-566.
37. Gorg P, Verma J, Roy N. 2008. In silico modeling for blood-brain barrier permeability protection. In Drug Absorption Studies. Springer: Berlin; 510-556.
38. Hammarlund-Udenaes M, Friden M, Syvanen S, Gupta A. 2008. On the rate and extent of drug delivery to the brain. Pharm. Res. 25: 1737-50; doi: 10.1007/s11095-007-9502-2.
39. Hansch C, Steward AR, Anderson SM, Bentley D. 1968a. The parabolic dependence of drug action upon lipophilic character as revealed by a study of hypnotics. J. Med. Chem. 11: 1-11; doi: 10.1021/jm00307a001.
40. Hansch C, Lien EJ, Helmer F. 1968b. Structure-activity correlations in the metabolism of drugs. Arch. Biochem. Biophys. 128: 319-330; doi: 10.1016/0003-9861(68)90038-6.
41. Hansch C, Steinmetz WE, Leo AJ, Mekapati SB, Kurup A, Hoekman D. 2003. On the role of polarizability in chemical-biological interactions. J. Chem. Inform. Comput. Sci. 43: 120-125; doi: 10.1021/ci020378b.
42. Hansch C, Leo A, Mekapati SB, Kurup A. 2004. QSAR and ADME, Bioorg. Med. Chem. 12: 3391-3400; doi: 10.1016/j.bmc.2003.11.037.
43. Hitchcock SA, Pennington LD. 2006. Structure-brain exposure relationships. J. Med. Chem. 49: 7559-7583; doi: 10.1021/jm060642i.
44. Hobbiger F. 1961. The inhibition of acetylcholinesterase by organophosphorus compounds and its reversal. Proc. R. Soc. Med. 54: 403-405.
45. Jiquidi M, Voicu VA, Ionescu-Visan I, Mircioiu C. 1980. Changes of toxicodynamic and toxicokinetics parameters of paraoxone by obidoxime (Roum.). Rev. San. Milit. 2: 182-188.
46. Jokanović M, Stojiljković MP. 2006. Current understanding of the application of pyridinium oximes as cholinesterase reactivators in treatment of organophosphate poisoning. Eur. J. Pharmacol. 553: 10-17; doi: 10.1016/j.ejphar.2006.09.054.
47. Jokanović, M., Prostran, M., 2009. Pyridinium oximes as cholinesterase reactivators. Structure-activity relationship and efficacy in the treatment of poisoning with organophosphorus compounds. Curr. Med. Chem. 16(17): 2177-2188; doi: 10.2174/092986709788612729.
48. Kassa J. 2002. Review of oximes in the antidotal treatment of poisoning by organophosphorus nerve agents. J. Toxicol. Clin. Toxicol. 40: 803-816; doi: 10.1081/CLT-120015840.
49. Kassa J, Karasova J. 2007. A comparison of the potency of newly developed oximes (K074, K075) and commonly used oximes (obidoxime, HI-6) to counteract tabun-induced neurotoxicity in rats. Toxicology 229: 136-144; doi: 10.1016/j.tox.2006.10.009.
50. Kassa J, Kunesova G. 2006. A comparison of the potency of newly developed oximes (K027, K048) and commonly used oximes (obidoxime, HI-6) to counteract tabun-induced neurotoxicity in rats. J. Appl. Toxicol. 26: 309-316; doi: 10.1002/jat.1137.
51. Kassa J, Jun D, Karasova J, Bajgar J, Kuca K. 2008a. A comparison of reactivating efficacy of newly developed oximes (K 074, K075) and currently available oximes (obidoxime, HI-6) in soman, cyclosarin and tabun-poisoned rats. Chem. Biol. Interact. 175: 425-427; doi: 10.1016/j.cbi.2008.05.001.
52. Kassa J, Karasova J, Musilek J, Kuca K. 2008b. An evaluation of therapeutic and reactivating effect of newly developed oximes (K 156, K 203) and commonly used oximes (obidoxime, trimedoxime and HI-6) in tabun-poisoned rats and mice. Toxicology 243: 311-316; doi: 10.1016/j.tox.2007.10.015.
53. Kassa J, Zdarova Karasova J, Pavlikova R, Misik J, Caisberger F, Bajgar J. 2010. The influence of combinations of oximes on the reactivating and therapeutic efficacy of antidotal treatment of tabun poisoning in rats and mice. J. Appl. Toxicol. 30: 120-124; doi: 10.1002/jat.1477.
54. Kenley RA, Howd RA, Uyeno ET. 1982. Effects of PAM, proPAM, and DFP on behavior, thermoregulation, and brain AChE in rats. Pharmacol. Biochem. Behav. 17: 1001-1008; doi: 10.1016/0091-3057(82)90485-3.
55. Lallement G, Carpentier P, Pernot-Marino I, Baubichon D, Collet A, Blanchet G. 1993. Transient impairment of the gabaergic function during initiation of soman-induced seizures. Brain Res. 629: 239-244; doi: 10.1016/0006-8993(93)91326-N.
56. Lallement G, Masqualiez C, Baubichon D, Cassegrain M, Renaudeau P, Clair P. 2004. Protection against soman-induced lethality of the antidote combination atropine-pralidoxime-pro-diazepam package as a freeze-dried form. J. Med. CBR Def. 2.
57. Ligtenstein DA, Kossen SP. 1983. Kinetic profile in blood and brain of the cholinesterase reactivating oxime HI-6 after intravenous administration to the rat. Toxicol. Appl. Pharmacol. 71: 177-183; doi: 10.1016/0041-008X(83)90334-4.
58. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug. Deliv. Rev. 46: 3-26; doi: 10.1016/S0169-409X(00)00129-0.
59. Lorke DE, Kalasz H, Petroianu GA, Tekes K. 2008. Entry of oximes into the brain: a review. Curr. Med. Chem. 15: 743-753; doi: 10.2174/092986708783955563.
60. Lundy PM, Shaw RK. 1983. Modification of cholinergically induced convulsive activity and cyclic GMP levels in the CNS. Neuropharmacology 22: 55-63. doi: 10.1016/0028-3908(83)90260-5.
61. Lundy PM, Shih TM. 1983. Examination of the role of central cholinergic mechanisms in the therapeutic effects of HI-6 in organophosphate poisoning. J. Neurochem. 40(5): 1321-1328.
62. Lundy PM, Raveh L, Amitai G. 2006. Development of the bisquaternary oxime HI-6 toward clinical use in the treatment of organophosphate nerve agent poisoning. Toxicol. Rev. 25: 231-243.
63. Marrs TC. 1991. Toxicology of oximes used in treatment of organophosphate poisoning. Adverse Drug React. Toxicol. Rev. 10: 61-73.
64. McDonough JH Jr, Shih TM. 1997. Neuropharmacological mechanisms of nerve agent-induced seizure and neuropathology. Neurosci. Biobehav. Rev. 21: 559-479; doi: 10.1016/S0149-7634(96)00050-4.
65. McDonough JH Jr, Zoeffel LD, McMonagle J, Copeland TL, Smith CD, Shih TM. 2000. Anticonvulsant treatment of nerve agent seizures: anticholinergics versus diazepam in soman-intoxicated guinea pigs. Epilepsy Res. 38: 1-14; doi: 10.1016/S0920-1211(99)00060-1.
66. Millard CB, Broomfield CA. 1995. Anticholinesterases: medical applications of neurochemical principles. J. Neurochem. 64: 1909-1918; doi: 10.1046/j.1471-4159.1995.64051909.x.
67. Musilek K, Dolezal M, Gunn-Moore F, Kuca K. 2009. Design, evaluation and structure-activity relationship studies of the AChE reactivators against organophosphorus pesticides. Med. Res. Rev.; doi: 10.1002/med.20192.
68. Myhrer T. 2007. Neuronal structures involved in the induction and propagation of seizures caused by nerve agents: implications for medical treatment. Toxicology 239: 1-14; doi: 10.1016/j.tox.2007.06.099.
69. O'Leary JF, Kunkel AM, Jones AH. 1961. Efficacy and limitations of oxime-atropine treatment of organophosphorus anticholinesterase poisoning. J. Pharmacol. Exp. Ther. 132: 50-57.
70. Pardridge WM. 2007. Brain drug development and brain drug targeting. Pharm. Res. 24(9): 1729-1732; doi: 10.1007/s11095-007-9324-2.
71. Rajapurkar MV, Koelle GB. 1958. Reactivation of DFP-inactivated acetylcholinesterase by monoisonitrosoacetone (MINA) and diacetylmonoxime (DAM) in vivo. J. Pharmacol. Exp. Ther. 123: 247-53.
72. Raveh L, Weissman BA, Cohen G, Alkalay D, Rabinovitz I, Sonego H, Brandeis R. 2002. Caramiphen and scopolamine prevent soman-induced brain damage and cognitive dysfunction. Neurotoxicology 23: 7-17; doi: 10.1016/S0161-813X(02)00005-0.
73. Raveh L, Brandeis R, Gilat E, Cohen G, Alkalay D, Rabinovitz I, Sonego H, Weissman BA. 2003. Anticholinergic and antiglutamatergic agents protect against soman-induced brain damage and cognitive dysfunction. Toxicol. Sci. 75: 108-116; doi: 10.1093/toxsci/kfg166.
74. Rump S, Kowalczy M, 2004. Management of convulsion in nerve agent acute poisoning: a polish perspective. J. Med. CBR Def. 1.
75. Rump S, Faff J, Borkowska G, Ilczuk I, Rabsztyn T. 1978. Central therapeutic effects of dihydroderivative of pralidoxime (pro-2-PAM) in organophosphate intoxication. Arch. Int. Pharmacodyn. Ther. 232: 321-332.
76. Rutland JP. 1958. The effect of some oximes in sarin poisoning. Br. J. Pharmacol. Chemother. 13: 399-403.
77. Santos MD, Pereira EF, Aracava Y, Castro NG, Fawcett WP, Randall WR, Albuquerque EX. 2003. Low concentrations of pyridostigmine prevent soman-induced inhibition of GABAergic transmission in the central nervous system: involvement of muscarinic receptors. J. Pharmacol. Exp. Ther. 304: 254-265; doi: 10.1124/jpet.102.043109.
78. Shih TM, McDonough JH Jr, Koplovitz I. 1999. Anticonvulsants for soman-induced seizure activity. J. Biomed. Sci. 6: 86-96; doi: 10.1007/BF02256439.
79. Shih TM, Duniho SM, McDonough JH. 2003. Control of nerve agent-induced seizures is critical for neuroprotection and survival. Toxicol. Appl. Pharmacol. 188: 69-80; doi: 10.1016/S0041-008X(03)00019-X.
80. Shih TM, Rowland TC, McDonough JH. 2007. Anticonvulsants for nerve agent-induced seizures: the influence of the therapeutic dose of atropine. J. Pharmacol. Exp. Ther. 320: 154-161; doi: 10.1124/jpet.106.111252.
81. Shih TM, Skovira JW, O'Donnell JC, McDonough JH. 2010. Treatment in tertiary oximes prevents seizures and improve survival following sarin intoxication. J. Mol. Neurosci. 40: 63-69; doi: 10.1007/s12031-009-9259-7.
82. Shrot S, Markel G, Dushnitsky T, Krivoy A. 2009. The possible use of oximes as antidotal therapy in organophosphate-induced brain damage. Neurotoxicology 30: 167-173; doi: 10.1016/j.neuro.2008.12.006.
83. Silva GR, Borges I, Figueroa-Villar JD, 2005. DFT conformational studies of the Hi-6 molecule, Int. J. Quantum Chem. 105: 260-269; doi: 10.1002/qua.20700.
84. Solberg Y, Belkin M. 1997. The role of excitotoxicity in organophosphorous nerve agents central poisoning. Trends Pharmacol. Sci. 18: 183-185; doi: 10.1016/S0165-6147(97)89540-5.
85. Summerfield SG, Stevens AJ, Cutler L, del Carmen Osuna M, Hammond B, Tang SP, Hersey A, Spalding DJ, Jeffrey P. 2006. Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. J. Pharmacol. Exp. Ther. 316: 1282-1290; doi: 10.1124/jpet.105.092916.
86. Summerfield SG, Read K, Begley DJ, Obradovic T, Hidalgo IJ, Coggon S, Lewis AV, Porter RA, Jeffrey P. 2007. Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction. J. Pharmacol. Exp. Ther. 322: 205-213; doi: 10.1124/jpet.107.121525.
87. Tanaka H, Mizojiri K. 1999. Drug-protein binding and blood-brain barrier permeability. J. Pharmacol. Exp. Ther. 288: 912-918.
88. van De Waterbeemd H, Smith DA, Beaumont K, Walker DK. 2001. Property-based design: optimization of drug absorption and pharmacokinetics. J. Med. Chem. 44: 1313-1333; doi: 10.1021/jm000407e.
89. van Helden HP, de Lange J, Busker RW, Melchers BP. 1991. Therapy of organophosphate poisoning in the rat by direct effects of oximes unrelated to ChE reactivation. Arch. Toxicol. 65: 586-593; doi: 10.1007/BF01973721.
90. van Helden HP, van der Wiel HJ, Zijlstra JJ, Melchers BP, Busker RW. 1994. Comparison of the therapeutic effects and pharmacokinetics of HI-6, HLö-7, HGG-12, HGG-42 and obidoxime following non-reactivatable acetylcholinesterase inhibition in rats. Arch. Toxicol. 68: 224-230; doi: 10.1007/s002040050061.
91. van Helden HP, Busker RW, Melchers BP, Bruijnzeel PL. 1996. Pharmacological effects of oximes: how relevant are they? Arch. Toxicol. 70: 779-786; doi: 10.1007/s002040050340.
92. Voicu VA, Miu C, Jiquidi M, Furnica C, Elian I. 1974. Medicine for control and treatment of toxic effects of organic-phosphoric compounds. RO Patent 79914.
93. Voicu VA, Jiquidi M, Sitcai N, Bruja N. 1976. Some pharmacological correlations of hypothermia induced by anticholinesterases. Rev. Roum. Physiology. 13: 285-91.
94. Voicu V, Sora I, Sârbu C, David V, Medvedovici A, 2010a. Hydrobhobicity/hydrophilicity descriptors obtained from extrapolated chromatographic retention data as modelling tools for biological distribution: application to some oxime type acetylcholinesterase reactivators. J. Pharm. Biomed. Anal. 52: 508-516; doi: 10.1016/j.jpba.2010.02.004.
95. Voicu V, Medvedovici A, Rǎdulescu M, Iorgulescu EE, David V, 2010b. Unusual retention behavior of some cationic-type aldoximes used as AchE reactivators under ion-pairing liquid chromatographic mechanism. Anal. Lett.; doi: 10.1080/00032710903518682.
96. Voicu VA, Thiermann H, Rǎdulescu F, Mircioiu C, Miron DS. 2010c. The toxicokinetics and toxicodynamics of organophosphonates versus the pharmacokinetics and pharmacodynamics of oxime antidotes: biological consequences. BCPT 106(2): 73-85; doi: 10.1111/j.1742-7843.2009.00486.x.
97. Worek F, Kirchner T, Szinicz L. 1995. Effect of atropine and bispyridinium oximes on respiratory and circulatory function in guinea-pigs poisoned by sarin. Toxicology 95: 123-133; doi: 10.1016/0300-483X(94)02891-W.